Piramal Pharma · NSE: PPLPHARMA · BSE: 543635
Q2 FY26 results · Jul–Sep 2025
Piramal Pharma reported revenue from operations of ₹2,043.72 crore (down 8.8% from Q2 FY25) and net loss of ₹99.22 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,043.72 | 2,241.75 | −8.8% | 1,933.71 | +5.7% |
| Other income | 65.60 | 61.11 | +7.3% | 58.40 | +12.3% |
| Total income | 2,109.32 | 2,302.86 | −8.4% | 1,992.11 | +5.9% |
| Profit before share of associates & JVs and tax | (60.97) | 102.86 | Turned loss | (97.59) | Loss narrowed |
| Share of profit/(loss) of associates & JVs | 14.79 | 17.26 | 18.57 | ||
| Net profit for the period | (99.22) | 22.59 | Turned loss | (81.70) | Loss widened |
| EPS, basic (₹) | (0.75) | 0.17 | Turned loss | (0.62) | Loss widened |
| Net margin (%) | -4.9 | 1.0 | -4.2 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,127.26 | 1,284.39 | −12.2% | 969.88 | +16.2% |
| Other income | 201.97 | 106.38 | +89.9% | 180.92 | +11.6% |
| Total income | 1,329.23 | 1,390.77 | −4.4% | 1,150.80 | +15.5% |
| Profit before tax | 247.41 | 275.71 | −10.3% | 142.58 | +73.5% |
| Net profit for the period | 196.33 | 210.06 | −6.5% | 113.14 | +73.5% |
| EPS, basic (₹) | 1.48 | 1.59 | −6.9% | 0.85 | +74.1% |
| Net margin (%) | 17.4 | 16.4 | 11.7 |
Consolidated
- Filed with BSE
- 05 Nov 2025, 21:04 IST
- Board meeting
- 05 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Nov 2025, 21:04 IST
- Board meeting
- 05 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE